Introduction
Methods
Setting, study design and patients
Definitions and outcome
Statistical analysis
Results
Variable | Missing | All patients | Heart failure | COPD | Heart failure and COPD | Neither heart failure nor COPD |
P
|
---|---|---|---|---|---|---|---|
N = 4986 | N = 1764 | N = 586 | N = 1750 | N = 886 | |||
Demographics | |||||||
Age (years) | 0 | 71 (± 11) | 71 (± 12) | 71 (± 10) | 75 (± 10) | 66 (± 12) | < 0.001 |
Sex (male)—N (%) | 0 | 3068 (62) | 1197 (68) | 273 (47) | 1139 (65) | 459 (52) | < 0.001 |
BMI (kg/m2) | 17 | 28.7 (± 6.0) | 29.1 (± 6.1) | 29.2 (± 5.6) | 27.4 (± 5.7) | 30.1 (± 6.2) | < 0.001 |
SR [N (%)] | 80 | 3562 (71) | 1087 (63) | 559 (96) | 1060 (62) | 3562 (73) | < 0.001 |
Diabetes [N (%)] | 308 | 970 (20) | 407 (24) | 80 (15) | 334 (21) | 149 (18) | < 0.001 |
IHD [N (%)] | 31 | 2259 (45) | 912 (52) | 151 (26) | 935 (54) | 261 (30) | < 0.001 |
Documented COPD in medical records [N (%)] | 31 | 478 (10) | 118 (7) | 86 (15) | 223 (13) | 51 (6) | < 0.001 |
Never smoked [N (%)] | 319 | 1421 (30) | 536 (33) | 158 (29) | 383 (24) | 344 (41) | < 0.001 |
Symptoms | |||||||
NYHA Class III/IV [N (%)] | 245 | 1344 (28) | 537 (31) | 90 (17) | 617 (36) | 100 (14) | < 0.001 |
Blood results | |||||||
NTproBNP [ng/L] | 461 | 723 (179–2045) | 1319 (656–2821) | 140 (73–228) | 1590 (742–3309) | 113 (57–203) | – |
Haemoglobin [g/dL] | 395 | 13.5 (12.3–14.5) | 13.4 (12.1–14.5) | 13.8 (12.9–14.7) | 13.2 (12.0–14.3) | 13.9 (13.0–14.9) | < 0.001 |
eGFR [mL/min/1.73 m2] | 346 | 62 (48–77) | 59 (44–74) | 71 (58–83) | 56 (42–70) | 74 (62–87) | < 0.001 |
Albumin [g/L] | 341 | 38 (36–40) | 38 (35–40) | 39 (37–40) | 37 (35–39) | 39 (37–41) | < 0.001 |
Spirometry | |||||||
FEV1 [L] | 0 | 1.76 (± 0.81) | 1.96 (± 0.76) | 1.51 (± 0.72) | 1.38 (± 0.60) | 2.30 (± 0.87) | < 0.001 |
FVC [L] | 0 | 2.58 (± 1.00) | 2.46 (± 0.95) | 2.78 (± 1.07) | 2.49 (± 0.95) | 2.87 (± 1.09) | < 0.001 |
FEV1:FVC | 0 | 0.69 (± 0.16) | 0.80 (0.09) | 0.54 (± 0.13) | 0.56 (± 0.12) | 0.80 (± 0.09) | – |
Medications | |||||||
Loop diuretic [N (%)] | 107 | 2932 (60) | 1240 (71) | 191 (34) | 1265 (73) | 236 (28) | < 0.001 |
MRA [N (%)] | 107 | 886 (18) | 443 (25) | 25 (5) | 382 (22) | 36 (4) | < 0.001 |
ACEI or ARB [N (%)] | 107 | 3142 (63) | 1266 (73) | 248 (44) | 1250 (72) | 378 (45) | < 0.001 |
βB [N (%)] | 107 | 2503 (50) | 1090 (63) | 170 (30) | 948 (55) | 295 (35) | < 0.001 |
Echocardiography | |||||||
Severe LVSD [N (%)] | 0 | 411 (8) | 207 (12) | 0 (0) | 204 (12) | 0 (0) | – |
HeFNEF [N (%)] | 0 | 1186 (24) | 583 (33) | 0 (0) | 603 (34) | 0 (0) | – |
Variable | Missing | All patients with heart failure | HeFREF | HeFNEF | HeFREF and COPD | HeFNEF and COPD |
P
|
---|---|---|---|---|---|---|---|
N = 3515 | N = 1181 | N = 583 | N = 1148 | N = 603 | |||
Demographics | |||||||
Age (years) | 0 | 73 (± 11) | 69 (± 12) | 75 (± 10) | 73 (± 10) | 77 (± 8) | < 0.001 |
Sex (male)—N (%) | 0 | 2336 (67) | 871 (74) | 326 (56) | 851 (74) | 288 (48) | < 0.001 |
BMI [kg/m2] | 13 | 28.3 (± 5.9) | 28.7 (± 5.7) | 29.9 (± 6.8) | 26.9 (± 5.2) | 28.4 (± 6.3) | < 0.001 |
SR [N (%)] | 65 | 2148 (62) | 809 (70) | 278 (48) | 754 (67) | 307 (52) | < 0.001 |
Diabetes [N (%)] | 206 | 742 (22) | 278 (25) | 129 (24) | 216 (20) | 119 (21) | 0.07 |
IHD [N (%)] | 12 | 1848 (53) | 713 (61) | 199 (35) | 735 (64) | 201 (33) | < 0.001 |
Documented COPD in medical records [N (%)] | 12 | 341 (10) | 74 (6) | 44 (8) | 149 (13) | 74 (12) | < 0.001 |
Never smoked [N (%)] | 237 | 919 (28) | 332 (30) | 204 (37) | 215 (20) | 168 (30) | < 0.001 |
Symptoms | |||||||
NYHA Class III/IV [N (%)] | 59 | 1154 (33) | 373 (33) | 164 (28) | 424 (38) | 193 (33) | < 0.001 |
Blood results | |||||||
NTproBNP (ng/L) | 461 | 1421 (695–3109) | 1444 (536–3486) | 1192 (737–2241) | 1825 (708–4013) | 1328 (773–2542) | < 0.001 |
Haemoglobin (g/dL) | 294 | 13.3 (12.1–14.4) | 13.6 (12.3–14.7) | 13.1 (11.8–14.2) | 13.3 (12.2–14.4) | 12.9 (11.7–14.2) | < 0.001 |
eGFR (mL/min/1.73 m2) | 287 | 58 (43–72) | 59 (46–74) | 59 (43–74) | 56 (43–70) | 56 (41–69) | < 0.001 |
Albumin (g/L) | 281 | 37 (35–40) | 38 (35–40) | 37 (35–39) | 37 (35–40) | 37 (34–39) | < 0.001 |
Spirometry | |||||||
FEV1:FVC | 0 | 0.68 (± 0.16) | 0.80 (± 0.10) | 0.80 (± 0.08) | 0.56 (± 0.12) | 0.56 (± 0.11) | < 0.001 |
Medications | |||||||
Loop diuretic [N (%)] | 37 | 2505 (72) | 872 (75) | 368 (64) | 857 (75) | 408 (68) | < 0.001 |
MRA [N (%)] | 37 | 825 (24) | 371 (32) | 72 (13) | 309 (27) | 73 (27) | < 0.001 |
ACEI or ARB [N (%)] | 37 | 2517 (72) | 906 (78) | 360 (62) | 890 (78) | 361 (61) | < 0.001 |
βB [N (%)] | 37 | 2039 (59) | 744 (64) | 346 (60) | 639 (56) | 310 (52) | < 0.001 |
Echocardiography | |||||||
Severe LVSD [N (%)] | 0 | 916 (26) | 457 (39) | 0 (0) | 459 (40) | 0 (0) | – |
LVEF by Simpsons (%) | 1511 | 38.2 (± 12.6) | 32.8 (± 8.0) | 54.6 (± 6.7) | 32.4 (± 8.2) | 55.8 (± 7.64) | – |